KONEXBiotech & Pharma233250

Median Diagnostics

₩4,800 0.00%2026-11-18 close
Market Cap
₩8.4B
Turnover
₩0
Volume
0 shares
Shares out.
1.8M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Earnings recovery, stalled trading

Earnings rose sharply in the 2025 settlement, but zero trading value and heavy controlling-shareholder concentration narrow how the share price can be read.

  1. 1

    On a standalone basis for the 2025 settlement, revenue fell 1.8% year on year, while operating profit rose 382.1% and net profit rose 97.3%.

  2. 2

    Per the 2024 business report, operating profit was KRW 490,575,285, turning positive from an operating loss of KRW 1,237,916,964 in 2023.

  3. 3

    Nanohelix and one other holder own 85.17% of the shares, and the free-float ratio is 9.14%.

  4. 4

    As of the close on September 8, 2026, trading volume and trading value were zero, and the 12-month change was -61.39%.

  5. 5

    On the 2025 settlement, WiseReport shows EPS of KRW 1,358, PER of 3.68x and PBR of 0.36x, while Hankyung's consensus data shows no 2026 consensus estimate.

02

Business structure

Median Diagnostics is a KONEX-listed company that develops, manufactures and sells in vitro diagnostic kits for animal diseases. Its product lineup is built on immunodiagnostic, molecular diagnostic and point-of-care technologies.

One pillar is diagnostic solutions aimed at nationally designated disasters and zoonotic infectious diseases, and the other is point-of-care diagnostic systems for companion-animal conditions. In 2024, on a consolidated basis, R&D expenses were KRW 2,595 million, equal to 21.28% of revenue.

Per the 2024 business report, revenue was KRW 12,165,641,614, close to the KRW 11,885,802,150 recorded in 2023. Because the business is concentrated in animal diagnostics, its structure differs clearly from the human-therapeutics focus of many domestic biopharma peers.

On the human side, the company previously obtained approval from the Ministry of Food and Drug Safety for a COVID-19 antigen self-test kit. A 2021 report indicates that its ASF rapid diagnostic kit for animals received full product approval from the Animal and Plant Quarantine Agency and was launched.

Its subsidiary Median Biotech Inc, established in January 2018, handles sales of veterinary medicines. Year-end 2024 headcount was 67.

03

Recent trends

On a standalone basis for the 2025 settlement, revenue fell 1.8% year on year. In the same settlement, operating profit rose 382.1% and net profit rose 97.3%. WiseReport summarized that revenue declined slightly while cost reduction significantly improved profitability.

Gross profit growth was attributed to stable production and quality control for immunodiagnostic kits and molecular diagnostic products, along with the launch of Rapid Kits and POCT PCR equipment.

Per the business report, 2024 operating profit was KRW 490,575,285, turning positive from an operating loss of KRW 1,237,916,964 in 2023. Over the same period, net profit was KRW 1,277,163,652, reversing a net loss of KRW 1,354,522,329 in 2023.

On the 2025 settlement, WiseReport shows EPS of KRW 1,358, PER of 3.68x and PBR of 0.36x. The stock closed at KRW 5,000 on September 8, 2026, moving within a 52-week range of KRW 4,600 to KRW 13,760.

Its 3-month change was -39.02% and its 12-month change was -61.39%, with trading volume and trading value recorded at zero. The current share price at the time of writing is KRW 4,800.

04

Outlook

The 2026 full-year estimate is blank in WiseReport's fundamentals table, and Hankyung's consensus data shows no consensus for the company.

Whether the cost reduction and gross profit growth cited as the basis of the 2025 return to profitability continue into 2026 quarterly results will be visible in quarterly report figures. The third-quarter 2026 report must be filed by November 14, 2026, which is within 45 days of quarter-end.

Because standalone revenue declined in 2025, the key question is how much new product launches and export expansion show up in quarterly sales. The company profile states that it is pursuing overseas market expansion and R&D in animal therapeutics and vaccines.

R&D spending equal to 21.28% of revenue in 2024 keeps the impact of R&D costs on the profit structure in focus. After the controlling stake changed in December 2024, the company profile lists Oh Jin-sik and Ko Min-su as co-CEOs.

Trading liquidity is shaped by the controlling holder's stake and the low free-float ratio, and trading volume trends will show this.

05

Bull factors

Core-technology product base

A 2021 report states the company holds 1,153 hybridoma clones and 82 virus and bacteria strains in-house, allowing direct development and production of antigens and antibodies.

Its ASF rapid fluorescence kit was described as having specificity above 99% and delivering results within 15 minutes from a very small blood sample of 0.04cc. A virus detection technology based on recombinant N-protein has been registered as a patent.

Growth outlook for companion-animal diagnostics

A 2021 KRX equity research report described the global companion-animal diagnostics market as expected to grow. That report cited a April 2021 global market trend study from the Korea Research Institute of Standards and Science-linked foundation for R&D special zones.

The company profile also lists national disaster diseases, zoonotic infections and companion-animal diagnostics together as its business areas. This outlook, however, rests on 2021 data and does not necessarily reflect the current market size.

Government commendation record

In December 2023 the company received a Minister of Agriculture, Food and Rural Affairs commendation for export contribution. In April 2024 it received a commendation from the head of the Gangwon regional public procurement service, and in June 2024 a Minister of Agriculture, Food and Rural Affairs commendation. These awards are recorded as recognition of both public procurement and export performance.

06

Bear factors

Stalled top-line growth

Profit metrics improved in the 2025 settlement, but standalone revenue declined, so the profit gain did not come from top-line expansion. The explanation attached to the results places more weight on cost reduction than on sales growth. On a revenue basis, a clear growth driver has not yet appeared.

Long-term shrinkage in market value

As of June 3, 2021, market capitalization stood at KRW 69.3 billion with a share price of KRW 39,700. As of the close on September 8, 2026, market capitalization was KRW 8.7 billion with a share price of KRW 5,000. Measured against the 52-week high of KRW 13,760, the share price has fallen sharply over the past year.

Ownership concentration and thin liquidity

Nanohelix and one other holder own 85.17% of the company. In December 2024, 1,252,894 shares held by the former largest shareholder were transferred to Nanohelix for a total consideration of KRW 21,001,009,228. With a free-float ratio of only 9.14%, the amount of shares available for trading is limited.

07

Risk factors

Macro

Interest rate levels and shifts in risk appetite can affect how quickly trading recovers in small KONEX-listed stocks. KONEX has fewer market participants than KOSPI or KOSDAQ, so broad capital flow changes tend to weigh heavily on individual stocks. Currency movements affect product profitability as the export share grows.

Regulatory and approval

Veterinary in vitro diagnostic products must receive product approval from the Animal and Plant Quarantine Agency before launch. Human diagnostic kits must meet approval and self-test standards set by the Ministry of Food and Drug Safety, and delays or standard changes can push back launch timing. Progress on new product approvals appears in disclosures and business reports.

Business concentration and governance

Revenue is concentrated in animal diagnostic products, so demand shifts in a single product line flow directly into total sales. With the largest shareholder group holding 85.17%, and changes in sales at subsidiary Median Biotech Inc, consolidated results could move as well. R&D spending equal to 21.28% of 2024 revenue can amplify earnings volatility.

08

Overall view

Median Diagnostics is a specialist in in vitro diagnostic kits for animal diseases, and in the 2025 settlement its revenue declined slightly while operating and net profit rose sharply.

The profit improvement came from cost reduction and higher gross profit, which is summarized as a positive factor in the business structure. On the other hand, a clear growth driver in revenue has not yet appeared, and R&D spending still accounts for a substantial share of sales.

The share price showed a 12-month change of -61.39% as of September 8, 2026, and trading volume and trading value were recorded at zero. The 85.17% stake held by the largest shareholder group and the 9.14% free-float ratio are read as structural factors that constrain trading liquidity.

With no 2026 consensus available, the basis for comparing earnings outlooks is also limited. The company has kept its focus on animal diagnostics after the December 2024 change in control. The stock is therefore summarized as a case where earnings recovery and weak trading coexist.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. markets.hankyung.com
  2. comp.wisereport.co.kr
  3. comp.wisereport.co.kr
  4. comp.wisereport.co.kr
  5. kind.krx.co.kr
  6. prestocknews.com
  7. ssl.pstatic.net
  8. econovill.com
  9. m.irgo.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis